Context Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive
and advanced prostate cancer, but it has also been associated with adverse effects on bone …

Androgen deprivation therapy remains a critical component of treatment for men with
advanced prostate cancer, and data support its use in metastatic disease and in conjunction …

Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer
decreases the number of deaths from this disease. Surrogates for overall survival (OS) could …

Importance Despite evidence demonstrating an overall survival benefit with up-front
hormone therapy in addition to established synergy between hormone therapy and …

Background Androgen-deprivation therapy is well-established for treating prostate cancer
but is associated with bone loss and an increased risk of fracture. We investigated the effects …

Purpose: Long-term prostate cancer specific mortality after radical prostatectomy is poorly
defined in the era of widespread screening. An understanding of the treated natural history …

Background Accurate detection of lymph-node metastases in prostate cancer is an essential
component of the approach to treatment. We investigated whether highly lymphotropic …

Purpose The role of adjuvant radiotherapy (aRT) in treating patients with pN1 prostate
cancer is controversial. We tested the hypothesis that the impact of aRT on cancer-specific …

ContextThe natural history of biochemical recurrence after radical prostatectomy can be long
but variable. Better risk assessment models are needed to identify men who are at high risk …

Purpose Androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH)
agonist is associated with increased fat mass and insulin resistance in men with prostate …